Consistently, agomelatine (AGO) inhibited Ube2c and induced improvement of synaptic plasticity and cognitive performance (Li T. et al., 2022), suggesting that Ube2c inhibitor may provide valuable insights in AD research. This evidence concerns the gene UBE2C and Alzheimer disease.